Navigation Links
AspenBio to Present at 2012 Aegis Healthcare Conference
Date:9/20/2012

s activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for AppyScore required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from AppyScore, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Final Prospectus filed on June 20, 2012.

For Investors & Media:
Joshua Drumm, Ph.D. / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com


'/>"/>
SOURCE AspenBio Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
4. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
5. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
6. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
7. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
8. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
9. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
10. PRA Expert to Present at Pharmacovigilance Conference
11. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015 ... developing next-generation antibiotics, today announced positive top-line results ... its lead drug candidate MRX-I. MRX-I is an ... such as MRSA and VRE, while offering physicians ... option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment ... is the first commercially available new FDA approved system in the last 14 years, ... 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Global & USA ... offering. The highly awaited US Biosimilar market ... highly awaited filigrastim biologic, Zarxio. How will the global ... The author reveals that biosimilars could save the US ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... Health Care Compliance Strategies, Inc. (HCCS) , ... training, today announced the release of a new online ... Associates (BAs) . Responding to expanded HIPAA Privacy Rule ... an online course designed to assist healthcare vendors in ...
... , a venture backed clinical stage biotechnology company developing ... from the Phase 2b trial of ARC-4558 for the ... will be the subject of two poster presentations at ... at the American Diabetes Association,s 71st Scientific Sessions, June ...
... Reportlinker.com announces that a new market research ... Global Immunochemicals Industry ... report analyzes the worldwide markets for Immunochemicals ... segments – Catalog Antibodies, and Custom Antibodies. ...
Cached Biology Technology:New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 2New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 3Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 2Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 3Reportlinker Adds Global Immunochemicals Industry 2Reportlinker Adds Global Immunochemicals Industry 3Reportlinker Adds Global Immunochemicals Industry 4Reportlinker Adds Global Immunochemicals Industry 5Reportlinker Adds Global Immunochemicals Industry 6Reportlinker Adds Global Immunochemicals Industry 7Reportlinker Adds Global Immunochemicals Industry 8Reportlinker Adds Global Immunochemicals Industry 9Reportlinker Adds Global Immunochemicals Industry 10
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Saudi Arabia Biomedical Sensors Market - ... offering. The Saudi Arabia Biomedical Sensors ... a CAGR of 3.64% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/24/2015)... The consulting company Frost & Sullivan ... DERMALOG and its customized solutions and products for ... the Year Award". DERMALOG is particularly successful with a large ... -Cross reference: Picture is available at AP Images ( ... Thursday evening, in South Africa,s economic ...
(Date:8/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... Smart Card Alliance and the EMV Migration Forum.  ... Smart Card Alliance Latin America (SCALA) Chapter provides NXT-ID, ... thought leaders promoting adoption of smart card technology. ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have ... into patients with diabetes who are suffering from critical ... complication of diabetes. The team of researchers in Seville, ... in a recent issue of Cell Transplantation ...
... of Alberta is working with scientists from across North America to ... 15 scientists will examine DNA samples from children with autism and ... risk. , , And if siblings are at high risk ... , If theres a family of a child with autism, they ...
... Boston In a breakthrough for the way brain cancer ... Anna M. Krichevsky, PhD, of the Center of Neurologic Diseases ... Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego ... reliably diagnosed and monitored without surgery. Previously, an accurate ...
Cached Biology News:Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations 2Researchers across North America team up to find genetic markers for autism 2
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
... of an N-terminal FLAG® fusion and a ... from bicistronic mRNA. Two genes can ... transcription of a single message from the ... protein-protein interaction studies, multi-subunit proteins, and cloning ...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Biology Products: